We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+11.16%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$1.09B
AUM Growth
+$89.1M
Cap. Flow
-$8.77M
Cap. Flow %
-0.8%
Top 10 Hldgs %
54.62%
Holding
69
New
7
Increased
12
Reduced
10
Closed
5

Top Buys

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$13.3M
2
INCY icon
Incyte
INCY
+$10.7M
3
PFE icon
Pfizer
PFE
+$10.1M
4
BMY icon
Bristol-Myers Squibb
BMY
+$9.98M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$5.12M

Top Sells

Rank Stock Value
1
PBYI icon
Puma Biotechnology
PBYI
+$19.4M
2
PRGO icon
Perrigo
PRGO
+$14.9M
3
AGN
Allergan Inc
AGN
+$9.3M
4
IBB icon
iShares Biotechnology ETF
IBB
+$8.72M
5
QCOR
QUESTCOR PHARMA INC
QCOR
+$7.6M

Sector Composition

Rank Sector Weight
1 Healthcare 88.61%
2 Financials 1.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GILD icon
1
Gilead Sciences
GILD
$163B
$125M 11.45%
1,504,712
– –
CELG
2
DELISTED
Celgene Corp
CELG
$81.1M 7.44%
944,092
– –
BIIB icon
3
Biogen
BIIB
$30.7B
$54.9M 5.04%
173,983
– –
REGN icon
4
Regeneron Pharmaceuticals
REGN
$77.4B
$54.6M 5.02%
193,466
-17,700
-8% -$5.25M
AMGN icon
5
Amgen
AMGN
$209B
$53.2M 4.88%
449,543
– –
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
$52.5M 4.82%
335,899
– –
VRTX icon
7
Vertex Pharmaceuticals
VRTX
$122B
$51.2M 4.7%
540,944
+41,180
+8% +$2.89M
AGN
8
DELISTED
Allergan plc
AGN
$45.9M 4.21%
205,707
– –
INCY icon
9
Incyte
INCY
$24.9B
$43.4M 3.98%
768,238
+210,158
+38% +$10.7M
VTRS icon
10
Viatris
VTRS
$20.7B
$33.6M 3.09%
652,209
– –
SHPG
11
DELISTED
Shire pic
SHPG
$29M 2.67%
123,322
-30,831
-20% -$5.36M
AGN
12
DELISTED
Allergan Inc
AGN
$26.5M 2.43%
156,627
-59,710
-28% -$9.3M
BMRN icon
13
BioMarin Pharmaceuticals
BMRN
$11.7B
$26.2M 2.41%
421,384
– –
AKRX
14
DELISTED
Akorn Inc
AKRX
$23.3M 2.13%
699,382
– –
AET
15
DELISTED
Aetna Inc
AET
$20.1M 1.84%
247,541
+700
+0.3% +$53K
ILMN icon
16
Illumina
ILMN
$31B
$18.5M 1.7%
106,749
– –
CBST
17
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
$18.4M 1.69%
263,772
+37,000
+16% +$2.52M
IBB icon
18
iShares Biotechnology ETF
IBB
$9.52B
$16.8M 1.54%
195,552
-110,688
-36% -$8.72M
TEVA icon
19
Teva Pharmaceuticals
TEVA
$41.2B
$16.3M 1.5%
311,476
– –
JAZZ icon
20
Jazz Pharmaceuticals
JAZZ
$16.2B
$14.1M 1.29%
+95,957
New +$13.3M
EIGR
21
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$13.2M 1.21%
2,157
– –
ALKS icon
22
Alkermes
ALKS
$8.39B
$12.9M 1.18%
255,970
+61,100
+31% +$2.82M
MCK icon
23
McKesson
MCK
$101B
$12.6M 1.16%
67,862
– –
IRWD icon
24
Ironwood Pharmaceuticals
IRWD
$614M
$11.8M 1.08%
917,052
– –
NBIX icon
25
Neurocrine Biosciences
NBIX
$18.7B
$11.7M 1.08%
790,490
+362,700
+85% +$5.12M
1
2 3

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2014 Portfolio in Review

As of Q2 2014, Tekla Capital Management held 69 positions worth $1.09B, up 8.9% from $1B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Tekla Capital Management's Q2 2014 filing shows 7 new, 12 increased, 10 reduced and 5 closed positions. Its largest new stake was Jazz Pharmaceuticals: 95,957 shares worth $14.1M. The largest sale was Puma Biotechnology, an estimated $19.4M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 87% a quarter earlier, followed by Financials.

  • Tekla Capital Management's largest Q2 2014 buy was Jazz Pharmaceuticals: 95,957 shares worth $14.1M.
  • Tekla Capital Management added most to Incyte in Q2 2014, an estimated $10.7M increase.
  • Tekla Capital Management's biggest Q2 2014 reduction was Perrigo, cutting an estimated $14.9M.
  • Tekla Capital Management fully exited Puma Biotechnology in Q2 2014, selling an estimated $19.4M.
  • Tekla Capital Management's ten largest holdings make up 55% of its $1.09B portfolio in Q2 2014.
  • Tekla Capital Management opened 7 new positions and closed 5 in Q2 2014.
  • Tekla Capital Management's portfolio value rose 8.9% quarter-over-quarter to $1.09B.

Based on Tekla Capital Management's 13F filing for Q2 2014, filed 5 Aug 2014.